1. Taramasso L, Dentone C, Cama I, Fenoglio D, et al.
   Distinct features of immune activation and exhaustion markers in people with perinatally-acquired HIV.
   AIDS 2024.
   


2. Neary J, Chebet D, Benki-Nugent S, Moraa H, et al.
   Association between HIV and cytomegalovirus and neurocognitive outcomes among children with HIV.
   AIDS 2024.
   


3. Siregar T, Weriditi RK, Reba YA, Muttaqin MZ, et al.
   Impact of COVID-19 vaccination on HIV parameters in people with HIV on antiretroviral therapy.
   AIDS 2024;38:1807-1808.
   


4. Clemente T, Pontillo D, Malagnino V, Calza L, et al.
   Cancer in people with multidrug-resistant HIV.
   AIDS 2024;38:1801-1806.
   


5. Leal M, Kerr L, Mota RMS, Motta-Castro ARC, et al.
   Increasing HIV prevalence rate among men who have sex with men: results of a comparison of two national surveys.
   AIDS 2024;38:1799-1801.
   


6. Gouvea-E-Silva LF.
   Challenges in clinical monitoring of people with HIV: evolution from prediabetes mellitus to diabetes mellitus.
   AIDS 2024;38:1796-1798.
   


7. Nicol MR, Dawood H, Hoy JF.
   Deconvoluting the contribution of antiretroviral choice in weight gain.
   AIDS 2024;38:1794-1795.
   


8. Crawford TN, Neilands TB, Drumright LN, Fredericksen RJ, et al.
   Internalized HIV stigma and viral suppression: examining the mediating and moderating roles of substance use and social support.
   AIDS 2024.
   


9. Hybel TE, Sorensen EF, Enemark MH, Hemmingsen JK, et al.
   Characterization of the genomic landscape of HIV-associated lymphoma reveals heterogeneity across histological subtypes.
   AIDS 2024.
   


10. Groenendijk AL, Miranda Afonso P, Wit F, Blaauw MJT, et al.
    The risk of non-AIDS defining events is lower in ART-naive HIV controllers than in normal progressors on suppressive ART.
    Clin Infect Dis 2024.
    


11. Ogbuagu O, Molina JM, Chetchotisakd P, Ramgopal MN, et al.
    Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial.
    Clin Infect Dis 2024.
    


12. Bosman S, Ayakaka I, Muhairwe J, Kamele M, et al.
    Evaluation of C-Reactive Protein and Computer-Aided Analysis of Chest X-rays as Tuberculosis Triage Tests at Health Facilities in Lesotho and South Africa.
    Clin Infect Dis 2024.
    


13. Gakuru J, Kagimu E, Dai B, Okurut S, et al.
    Implementation of single high-dose liposomal amphotericin B based induction therapy for treatment of HIV-associated cryptococcal meningitis in Uganda: a comparative prospective cohort study.
    Clin Infect Dis 2024.
    


14. Walters MK, Korenromp EL, Yakusik A, Wanyeki I, et al.
    Guidance for triangulating data and estimates of HIV prevalence among pregnant women and coverage of PMTCT using the Spectrum AIDS Impact Module.
    J Acquir Immune Defic Syndr 2024.
    


15. Serrano-Risquez C, Omar M, Rallon N, Benito JM, et al.
    Impact of HLA allele-KIR partners on sexually transmitted HIV-1 infection.
    J Infect Dis 2024.
    


16. Serrano-Villar S, Gala A, Bacchetti P, Hoh R, et al.
    Galectin-9 Levels as a Potential Predictor of Intact HIV Reservoir Decay.
    J Infect Dis 2024.
    


17. Okafor EC, Mukaremera L, Hullsiek KH, Engen N, et al.
    CSF Cytokines and Chemokines Involved in Cytotoxic Cell Function and Risk of Acute 14-Day Mortality in Persons with Advanced HIV and Cryptococcal Meningitis.
    J Infect Dis 2024.
    


18. An M, Zheng C, Chen L, Li H, et al.
    Sustained Spread of HIV-1 CRF55_01B in Its Place of Initial Origin: Dynamics and Hotspots.
    J Infect Dis 2024.
    


19. Chaimongkol N, Kim DY, Matsushima Y, Durkee-Shock J, et al.
    A Decade of Chronic Norovirus Infection Surveillance at the NIH Clinical Research Center: Clinical Characteristics, Molecular Epidemiology, and Replication.
    J Infect Dis 2024.
    


20. Patel D, Mulatu MS, Wang G, May AC, et al.
    CDC-Funded HIV Testing Services Outcomes in Ending the HIV Epidemic in the U.S. (EHE) and Non-EHE Jurisdictions, 2021.
    J Infect Dis 2024.
    


21. Ye J, Dong Y, Lan Y, Chen J, et al.
    Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023.
    J Infect Dis 2024.
    


22. Ye J, Lan Y, Wang J, Feng Y, et al.
    Improvement in the 95-95-95 Targets Is Accompanied by a Reduction in Both the Human Immunodeficiency Virus Transmission Rate and Incidence in China.
    J Infect Dis 2024.
    


23. Passerini S, Fracella M, Benvenuto D, Bugani G, et al.
    High rates of anal Merkel Cell Polyomavirus and HPV co-infection among people living with HIV.
    J Med Virol 2024;96:e29883.
    


24. Foury A, Saunier A, Taverniers A, Pinet N, et al.
    The relevance of ultradeep sequencing for low HIV-1 viral loads and proviruses in the clinical setting.
    J Med Virol 2024;96:e29870.
    


25. Brackenridge S, John N, He W, Fruh K, et al.
    Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins.
    J Virol 2024.
    


26. Bassey AE.
    The health of migrants at the intersection of mpox and HIV.
    Lancet 2024.
    


27. Hemono R, Gatare E, Kayitesi L, Hunter LA, et al.
    Effect of a digital school-based intervention on adolescent family planning and reproductive health in Rwanda: a cluster-randomized trial.
    Nat Med 2024.
    


28. Nachega JB, Mohr EL, Dashraath P, Mbala-Kingebeni P, et al.
    Mpox in Pregnancy - Risks, Vertical Transmission, Prevention, and Treatment.
    N Engl J Med 2024.
    

Display articles in

• Abstract format
• Medline format